Replies to post #120870 on Biotech Values

[Kadaicher1]

Repeat, not pumping this stock and dont hold. I just find this interesting because it is the second half of Prana's MOA, which I do hold. Prana's PBT2 breaks up the plaques by removing the zinc from the synapses and plaques, releasing it for use where it is needed.
A recent addition to the scientific advisory board is Prana's
Ashley Bush.
A 2003 quote. [In retrospect, Bush concedes he was treated fairly by the NIH. "I just chose to pursue a subject that defied fashion," he says. "A good scientist needs a thick skin and an irrational sense of optimism."]

Bush comments when he signed on to their advisory board.
"It's interesting. It's a different spin," said Bush, describing Ade-ona's approach to market a zinc compound as a nutritional supplement. "Beta amyloid makes the brain zinc-deficient, so you might think a zinc supplement would work. But what if the amyloid traps the zinc and keeps it from getting into the brain?

"Whether or not it will be effective in trials is the question, of course. They'll have to capture that effect in the clinical trial, but the approach is at least safe. And it's cheap. Good luck to them."

His comments on this trial.

A. Bush:
"The biological availability of zinc is impaired in Alzheimer's disease as evidenced by significantly lower plasma zinc levels and deficiencies of neuronal zinc activities, each of which are further exacerbated with age. The recent clinical study of reaZin showed that the oral treatment is well-tolerated, and there are even trends to benefits in cognitive outcomes over the study period in several readouts.

Based on the consistencies in these trends, the prevalence of abnormally low plasma zinc levels in the elderly, and the established detrimental effects of chronic zinc deficiency on cognition, I think it is very reasonable to test for the ability of reaZin to ameliorate cognitive decline in a larger-scale clinical trial," said Ashley I. Bush, M.D., Ph.D., Head of the Oxidation Disorders Laboratory for the Mental Health Research Institute, University of Melbourne and Adeona Scientific Advisory Board member."